Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733492 | 0.98 | CHRM1 (0.30) | CHRM1 | |
| SCHEMBL12733478 | 0.84 | DPP4 (0.31) | CNR2DPP4 | |
| SCHEMBL12733483 | 0.82 | CHRM1 (0.30) | CHRM1 | |
| SCHEMBL12733496 | 0.77 | CFD (0.30) | — | |
| SCHEMBL12733477 | 0.75 | CYP3A4 (0.44) | CNR2DPP4CHRM1 | |
| SCHEMBL2604735 | 0.73 | CYP3A4 (0.46) | CNR2DPP4CHRM1 | |
| SCHEMBL12806509 | 0.72 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL12733495 | 0.69 | L3MBTL1 (0.34) | — | |
| SCHEMBL12733489 | 0.69 | L3MBTL1 (0.34) | — | |
| SCHEMBL11194198 | 0.67 | ATM (0.39) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234205-A1 | Antineoplastic peptides | BCL2A1, ETF1, BAK1 | CNR2 3038/4885DPP4 3919/4885CHRM1 3857/4885 |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | BCL2A1, CSTB, BAK1 | CNR2 3310/4885DPP4 4251/4885CHRM1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.